Michael Kozal, MD

• Amy Justice
• Christopher Ruser
• Erol Fikrig
• Frederick Lewis Altice
• Gerald Friedland
• Heidi J Zapata
• Jeanette Tetrault
• Jennifer Chiarella
• John Solomon Francis
• Joseph Lucien Goulet
• Louise-Marie Dembry
• Lydia Aoun-Barakat
• Sandra Ann Springer
• Shaili Gupta
• Sheela Shenoi
• Sheldon Campbell
• Steven Farber
• Tassos C. Kyriakides

Acquired Immunodeficiency Syndrome; Clinical Trials as Topic; Drug Resistance; Hepatitis C; HIV; Veterans; Infectious Disease Medicine

• Academic Medical Centers and the U.S. Department of Veterans Affairs: A 75-Year Partnership Influences Medical Education, Scientific Discovery, and Clinical CarePetrakis IL, Kozal M. Academic Medical Centers and the U.S. Department of Veterans Affairs: A 75-Year Partnership Influences Medical Education, Scientific Discovery, and Clinical Care Academic Medicine 2022, 97: 1110-1113. PMID: 35507451, DOI: 10.1097/acm.0000000000004734.
• Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1Gartland M, Cahn P, DeJesus E, Diaz RS, Grossberg R, Kozal M, Kumar P, Molina JM, Urbina F, Wang M, Du F, Chabria S, Clark A, Garside L, Krystal M, Mannino F, Pierce A, Ackerman P, Lataillade M. Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1 Antimicrobial Agents And Chemotherapy 2022, 66: e01751-21. PMID: 35502922, PMCID: PMC9211436, DOI: 10.1128/aac.01751-21.
• Fostemsavir: a first-in-class HIV-1 attachment inhibitorGrant PM, Kozal MJ. Fostemsavir: a first-in-class HIV-1 attachment inhibitor Current Opinion In HIV And AIDS 2022, 17: 32-35. PMID: 34871189, DOI: 10.1097/coh.0000000000000712.
• Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individualsMoldt B, Günthard HF, Workowski KA, Little SJ, Eron JJ, Overton ET, Lehmann C, Rokx C, Kozal MJ, Gandhi RT, Braun DL, Parvangada A, Li J, Martin R, Selzer L, Cox S, Margot N, Liu H, Slamowitz D, Makadzange T, Collins SE, Geleziunas R, Callebaut C. Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals AIDS 2021, 36: 205-214. PMID: 34586088, DOI: 10.1097/qad.0000000000003088.
• Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1Ackerman P, Thompson M, Molina JM, Aberg J, Cassetti I, Kozal M, Castagna A, Martins M, Ramgopal M, Sprinz E, Treviño-Pérez S, Streinu-Cercel A, Latiff GH, Pialoux G, Kumar PN, Wang M, Chabria S, Pierce A, Llamoso C, Lataillade M. Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1 AIDS 2021, 35: 1061-1072. PMID: 33946085, PMCID: PMC8183480, DOI: 10.1097/qad.0000000000002851.
• Fostemsavir for the treatment of HIVSeval N, Frank C, Kozal M. Fostemsavir for the treatment of HIV Expert Review Of Anti-infective Therapy 2021, 19: 961-966. PMID: 33331202, DOI: 10.1080/14787210.2021.1865801.
• ANÁLISE DE SUBGRUPO DOS RESULTADOS DE EFICÁCIA E SEGURANÇA DA SEMANA 96 AVALIANDO O FOSTEMSAVIR EM PARTICIPANTES INFECTADOS POR HIV‐1 EXTENSAMENTE EXPERIMENTADOS AO TRATAMENTO NO ESTUDO DE FASE 3 BRIGHTE: RESULTADOS DA COORTE RANDOMIZADAAckerman P, Aberg J, Molina J, Cassetti I, Kozal M, Treviño‐Pérez S, Streinu‐Cercel A, Latiff G, Zajdenverg R, Sprinz E. ANÁLISE DE SUBGRUPO DOS RESULTADOS DE EFICÁCIA E SEGURANÇA DA SEMANA 96 AVALIANDO O FOSTEMSAVIR EM PARTICIPANTES INFECTADOS POR HIV‐1 EXTENSAMENTE EXPERIMENTADOS AO TRATAMENTO NO ESTUDO DE FASE 3 BRIGHTE: RESULTADOS DA COORTE RANDOMIZADA The Brazilian Journal Of Infectious Diseases 2021, 25: 101055. DOI: 10.1016/j.bjid.2020.101055.
• Transmitted HIV‐1 drug resistance in a large international cohort using next‐generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) studyBaxter J, Dunn D, Tostevin A, Marvig R, Bennedbæk M, Cozzi‐Lepri A, Sharma S, Kozal M, Gompels M, Pinto A, Lundgren J, Group F. Transmitted HIV‐1 drug resistance in a large international cohort using next‐generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study HIV Medicine 2020, 22: 360-371. PMID: 33369017, PMCID: PMC8049964, DOI: 10.1111/hiv.13038.
• Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE studyLataillade M, Lalezari JP, Kozal M, Aberg JA, Pialoux G, Cahn P, Thompson M, Molina JM, Moreno S, Grinsztejn B, Diaz RS, Castagna A, Kumar PN, Latiff GH, De Jesus E, Wang M, Chabria S, Gartland M, Pierce A, Ackerman P, Llamoso C. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study The Lancet HIV 2020, 7: e740-e751. PMID: 33128903, DOI: 10.1016/s2352-3018(20)30240-x.
• SARS-CoV-2 detection in setting of viral swabs scarcity: Are MRSA swabs and viral swabs equivalent?Federman DG, Gupta S, Stack G, Campbell SM, Peaper DR, Dembry LM, Fisher A, Tarabar AF, Kozal M, Ruser CB. SARS-CoV-2 detection in setting of viral swabs scarcity: Are MRSA swabs and viral swabs equivalent? PLOS ONE 2020, 15: e0237127. PMID: 32756602, PMCID: PMC7406068, DOI: 10.1371/journal.pone.0237127.
• Fostemsavir in Adults with Multidrug-Resistant HIV-1 InfectionKozal M, Aberg J, Pialoux G, Cahn P, Thompson M, Molina JM, Grinsztejn B, Diaz R, Castagna A, Kumar P, Latiff G, DeJesus E, Gummel M, Gartland M, Pierce A, Ackerman P, Llamoso C, Lataillade M. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection New England Journal Of Medicine 2020, 382: 1232-1243. PMID: 32212519, DOI: 10.1056/nejmoa1902493.
• Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disordersFuchs M, Monto A, Bräu N, Charafeddine M, Schmidt W, Kozal M, Naggie S, Cheung R, Schnell G, Yu Y, Richards K, Mullally V, Cohen DE, Toro D. Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders Journal Of Medical Virology 2020, 92: 3459-3464. PMID: 31829433, PMCID: PMC7687116, DOI: 10.1002/jmv.25655.
• Computer Use in the HIV Primary Care Clinic: Patient and Provider PerspectivesA Y, C F, Q W, F L, LA B, MJ K. Computer Use in the HIV Primary Care Clinic: Patient and Provider Perspectives Journal Of HIV And AIDS 2018, 4 DOI: 10.16966/2380-5536.158.
• Characterizing Patients with Very-Low-Level HIV Viremia: A Community-Based StudyHelou E, Shenoi S, Kyriakides T, Landry ML, Kozal M, Barakat LA. Characterizing Patients with Very-Low-Level HIV Viremia: A Community-Based Study Journal Of The International Association Of Providers Of AIDS Care (JIAPAC) 2016, 16: 261-266. PMID: 27903948, PMCID: PMC5423832, DOI: 10.1177/2325957416680028.
• HIV Drug Resistance Mutations (DRMs) Detected by Deep Sequencing in Virologic Failure Subjects on Therapy from Hunan Province, ChinaChen X, Zou X, He J, Zheng J, Chiarella J, Kozal MJ. HIV Drug Resistance Mutations (DRMs) Detected by Deep Sequencing in Virologic Failure Subjects on Therapy from Hunan Province, China PLOS ONE 2016, 11: e0149215. PMID: 26895182, PMCID: PMC4760947, DOI: 10.1371/journal.pone.0149215.
• DHHS/NIH Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Panel Member/Author. Released January 28, 2016.https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/1/panel-roster
• A Study of the Knowledge and Beliefs Held by Patients Infected With HIV and Their HIV Healthcare Providers Regarding Single-Tablet Regimens (STR). (KNABSTR Study)Frank C, Kyriakides T, Omar A, Friedland G, Andrews L, Melbourne K, Kozal M. A Study of the Knowledge and Beliefs Held by Patients Infected With HIV and Their HIV Healthcare Providers Regarding Single-Tablet Regimens (STR). (KNABSTR Study) Open Forum Infectious Diseases 2015, 2: 1082. DOI: 10.1093/ofid/ofv133.795.
• Deep sequencing of HIV-1 variants from paired plasma and cerebrospinal fluid during primary HIV infectionGega A, Kozal MJ, Chiarella J, Lee E, Peterson J, Hecht FM, Liegler T, St John EP, Simen BB, Price RW, Spudich SS. Deep sequencing of HIV-1 variants from paired plasma and cerebrospinal fluid during primary HIV infection Journal Of Virus Eradication 2015, 1: 264-268. PMID: 26855971, PMCID: PMC4743659, DOI: 10.1016/s2055-6640(20)30926-2.
• Increased Levels of Macrophage Inflammatory Proteins Result in Resistance to R5-Tropic HIV-1 in a Subset of Elite ControllersWalker WE, Kurscheid S, Joshi S, Lopez CA, Goh G, Choi M, Barakat L, Francis J, Fisher A, Kozal M, Zapata H, Shaw A, Lifton R, Sutton RE, Fikrig E. Increased Levels of Macrophage Inflammatory Proteins Result in Resistance to R5-Tropic HIV-1 in a Subset of Elite Controllers Journal Of Virology 2015, 89: 5502-5514. PMID: 25740989, PMCID: PMC4442529, DOI: 10.1128/jvi.00118-15.
• Transmitted HIV‐1 resistance in STARTBaxter J, Dunn D, White E, Sharma S, Geretti A, Kozal M, Johnson M, Jacoby S, Llibre J, Lundgren J, Group I. Transmitted HIV‐1 resistance in START HIV Medicine 2015, 16: 77-87. PMID: 25711326, PMCID: PMC4341921, DOI: 10.1111/hiv.12236.
• Transmission of HIV drug resistanceGeretti AM, Paredes R, Kozal MJ. Transmission of HIV drug resistance Current Opinion In Infectious Diseases 2015, 28: 23-30. PMID: 25501541, DOI: 10.1097/qco.0000000000000136.
• Low-Frequency NNRTI-Resistant HIV-1 Variants and Relationship to Mutational Load in Antiretroviral-Naïve SubjectsGupta S, Lataillade M, Kyriakides TC, Chiarella J, St. John EP, Webb S, Moreno EA, Simen BB, Kozal MJ. Low-Frequency NNRTI-Resistant HIV-1 Variants and Relationship to Mutational Load in Antiretroviral-Naïve Subjects Viruses 2014, 6: 3428-3437. PMID: 25256391, PMCID: PMC4189030, DOI: 10.3390/v6093428.
• Prevalence of WHO Transmitted Drug Resistance Mutations by Deep Sequencing in Antiretroviral-Naïve Subjects in Hunan Province, ChinaXiaobai Z, Xi C, Tian H, Williams AB, Wang H, He J, Zhen J, Chiarella J, Blake LA, Turenchalk G, Kozal MJ. Prevalence of WHO Transmitted Drug Resistance Mutations by Deep Sequencing in Antiretroviral-Naïve Subjects in Hunan Province, China PLOS ONE 2014, 9: e98740. PMID: 24896087, PMCID: PMC4045886, DOI: 10.1371/journal.pone.0098740.
• Deep Sequencing of HIV: Clinical and Research ApplicationsChabria SB, Gupta S, Kozal MJ. Deep Sequencing of HIV: Clinical and Research Applications Annual Review Of Genomics And Human Genetics 2014, 15: 1-31. PMID: 24821496, DOI: 10.1146/annurev-genom-091212-153406.
• O64 EFFECT OF BASELINE NS5A POLYMORPHISMS ON VIROLOGIC RESPONSE TO THE ALL-ORAL COMBINATION OF DACLATASVIR + SOFOSBUVIR ± RIBAVIRIN IN PATIENTS WITH CHRONIC HCV INFECTIONMcPhee F, Zhou N, Yang X, Hernandez D, Chiarella J, Kozal M. O64 EFFECT OF BASELINE NS5A POLYMORPHISMS ON VIROLOGIC RESPONSE TO THE ALL-ORAL COMBINATION OF DACLATASVIR + SOFOSBUVIR ± RIBAVIRIN IN PATIENTS WITH CHRONIC HCV INFECTION Journal Of Hepatology 2014, 60: s26-s27. DOI: 10.1016/s0168-8278(14)60066-0.
• The VACS Index Accurately Predicts Mortality and Treatment Response among Multi-Drug Resistant HIV Infected Patients Participating in the Options in Management with Antiretrovirals (OPTIMA) StudyBrown ST, Tate JP, Kyriakides TC, Kirkwood KA, Holodniy M, Goulet JL, Angus BJ, Cameron DW, Justice AC, . The VACS Index Accurately Predicts Mortality and Treatment Response among Multi-Drug Resistant HIV Infected Patients Participating in the Options in Management with Antiretrovirals (OPTIMA) Study PLOS ONE 2014, 9: e92606. PMID: 24667813, PMCID: PMC3965438, DOI: 10.1371/journal.pone.0092606.
• Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 StudyCastagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, Molina J, Chas J, Durant J, Moreno S, Doroana M, Ait-Khaled M, Huang J, Min S, Song I, Vavro C, Nichols G, Yeo J, , Aberg J, Akil B, Arribas J, Baril J, Blanco Arévalo J, Blanco Quintana F, Blick G, Boix Martínez V, Bouchaud O, Branco T, Bredeek U, Castro Iglesias M, Clumeck N, Conway B, DeJesus E, Delassus J, De Truchis P, Di Perri G, Di Pietro M, Duggan J, Duvivier C, Elion R, Eron J, Fish D, Gathe J, Haubrich R, Henderson H, Hicks C, Hocqueloux L, Hodder S, Hsiao C, Katlama C, Kozal M, Kumar P, Lalla-Reddy S, Lazzarin A, Leoncini F, Llibre J, Mansinho K, Morlat P, Mounzer K, Murphy M, Newman C, Nguyen T, Nseir B, Philibert P, Pialoux G, Poizot-Martin I, Ramgopal M, Richmond G, Salmon Ceron D, Sax P, Scarsella A, Sension M, Shalit P, Sighinolfi L, Sloan L, Small C, Stein D, Tashima K, Tebas P, Torti C, Tribble M, Troisvallets D, Tsoukas C, Viciana Fernández P, Ward D, Wheeler D, Wilkin T, Yeni G, Louise Martin-Carpenter J, Uhlenbrauck G. Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study The Journal Of Infectious Diseases 2014, 210: 354-362. PMID: 24446523, PMCID: PMC4091579, DOI: 10.1093/infdis/jiu051.
• Association Between Risk Behaviors and Antiretroviral Resistance in HIV-Infected Patients Receiving Opioid Agonist TreatmentTetrault JM, Kozal MJ, Chiarella J, Sullivan LE, Dinh AT, Fiellin DA. Association Between Risk Behaviors and Antiretroviral Resistance in HIV-Infected Patients Receiving Opioid Agonist Treatment Journal Of Addiction Medicine 2013, 7: 102-107. PMID: 23388678, PMCID: PMC3618545, DOI: 10.1097/adm.0b013e31827f9bdf.
• A Study of Financial Incentives to Reduce Plasma HIV RNA Among Patients in CareFarber S, Tate J, Frank C, Ardito D, Kozal M, Justice AC, Scott Braithwaite R. A Study of Financial Incentives to Reduce Plasma HIV RNA Among Patients in Care AIDS And Behavior 2013, 17: 2293-2300. PMID: 23404097, PMCID: PMC3742414, DOI: 10.1007/s10461-013-0416-1.
• Impact of Minority Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Resistance Genotype After Virologic FailureLi JZ, Paredes R, Ribaudo HJ, Kozal MJ, Svarovskaia ES, Johnson JA, Geretti AM, Metzner KJ, Jakobsen MR, Hullsiek KH, Ostergaard L, Miller MD, Kuritzkes DR. Impact of Minority Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Resistance Genotype After Virologic Failure The Journal Of Infectious Diseases 2012, 207: 893-897. PMID: 23264671, PMCID: PMC3571444, DOI: 10.1093/infdis/jis925.
• Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor Mutations with Protease and Reverse Transcriptase Resistance MutationsWinters MA, Lloyd RM, Shafer RW, Kozal MJ, Miller MD, Holodniy M. Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor Mutations with Protease and Reverse Transcriptase Resistance Mutations PLOS ONE 2012, 7: e40514. PMID: 22815755, PMCID: PMC3399858, DOI: 10.1371/journal.pone.0040514.
• A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study ResultsKozal MJ, Lupo S, DeJesus E, Molina JM, McDonald C, Raffi F, Benetucci J, Mancini M, Yang R, Wirtz V, Percival L, Zhang J, Zhu L, Arikan D, Farajallah A, Nguyen BY, Leavitt R, McGrath D, Lataillade M, Team F. A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results HIV Research & Clinical Practice 2012, 13: 119-130. PMID: 22592092, DOI: 10.1310/hct1303-119.
• Virologic Failures on Initial Boosted-PI Regimen Infrequently Possess Low-Level Variants with Major PI Resistance Mutations by Ultra-Deep SequencingLataillade M, Chiarella J, Yang R, DeGrosky M, Uy J, Seekins D, Simen B, St. John E, Moreno E, Kozal M. Virologic Failures on Initial Boosted-PI Regimen Infrequently Possess Low-Level Variants with Major PI Resistance Mutations by Ultra-Deep Sequencing PLOS ONE 2012, 7: e30118. PMID: 22355307, PMCID: PMC3280244, DOI: 10.1371/journal.pone.0030118.
• Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failureLi JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Kozal MJ, Hullsiek KH, Miller MD, Bangsberg DR, Kuritzkes DR. Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure AIDS 2012, 26: 185-192. PMID: 22179227, PMCID: PMC3437231, DOI: 10.1097/qad.0b013e32834e9d7d.
• Prevalence of Low-Level HIV-1 Variants with Reverse Transcriptase Mutation K65R and the Effect of Antiretroviral Drug Exposure on Variant LevelsKozal MJ, Chiarella J, St John EP, Moreno EA, Simen BB, Arnold TE, Lataillade M. Prevalence of Low-Level HIV-1 Variants with Reverse Transcriptase Mutation K65R and the Effect of Antiretroviral Drug Exposure on Variant Levels Antiviral Therapy 2011, 16: 925-929. PMID: 21900725, DOI: 10.3851/imp1851.
• Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure: A Systematic Review and Pooled AnalysisLi JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, Hullsiek KH, Balduin M, Jakobsen MR, Geretti AM, Thiebaut R, Ostergaard L, Masquelier B, Johnson JA, Miller MD, Kuritzkes DR. Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure: A Systematic Review and Pooled Analysis JAMA 2011, 305: 1327-1335. PMID: 21467286, PMCID: PMC3325645, DOI: 10.1001/jama.2011.375.
• Epidemiology, Seasonality, and Predictors of Outcome of AIDS-Associated Penicillium marneffei Infection in Ho Chi Minh City, Viet NamLe T, Wolbers M, Chi NH, Quang VM, Chinh NT, Lan NP, Lam PS, Kozal MJ, Shikuma CM, Day JN, Farrar J. Epidemiology, Seasonality, and Predictors of Outcome of AIDS-Associated Penicillium marneffei Infection in Ho Chi Minh City, Viet Nam Clinical Infectious Diseases 2011, 52: 945-952. PMID: 21427403, PMCID: PMC3106230, DOI: 10.1093/cid/cir028.
• New technology to detect low-level drug-resistant HIV variantsGega A, Kozal M. New technology to detect low-level drug-resistant HIV variants Future Virology 2011, 6: 17-26. DOI: 10.2217/fvl.10.77.
• Does the duration of untreated psychosis affect prognosis in schizophrenia?Mayer G, Dekel I, Domrab A, Drobot M, Guttnik Y, Kalman E, Kozal M, Yifat I. Does the duration of untreated psychosis affect prognosis in schizophrenia? Israel Journal Of Psychiatry And Related Sciences 2011, 48: 140-1. PMID: 22120454.
• Prevalence and Clinical Significance of HIV Drug Resistance Mutations by Ultra-Deep Sequencing in Antiretroviral-Naïve Subjects in the CASTLE StudyLataillade M, Chiarella J, Yang R, Schnittman S, Wirtz V, Uy J, Seekins D, Krystal M, Mancini M, McGrath D, Simen B, Egholm M, Kozal M. Prevalence and Clinical Significance of HIV Drug Resistance Mutations by Ultra-Deep Sequencing in Antiretroviral-Naïve Subjects in the CASTLE Study PLOS ONE 2010, 5: e10952. PMID: 20532178, PMCID: PMC2880604, DOI: 10.1371/journal.pone.0010952.
• Use of new technologies to detect and understand HIV drug resistanceKozal M. Use of new technologies to detect and understand HIV drug resistance Retrovirology 2010, 7: i19. PMCID: PMC3315900, DOI: 10.1186/1742-4690-7-s1-i19.
• Development of an Electronic Medical Record-Based Clinical Decision Support Tool to Improve HIV Symptom ManagementNader CM, Tsevat J, Justice AC, Mrus JM, Levin F, Kozal MJ, Mattocks K, Farber S, Rogers M, Erdos J, Brandt C, Kudel I, Braithwaite R. Development of an Electronic Medical Record-Based Clinical Decision Support Tool to Improve HIV Symptom Management AIDS Patient Care And STDs 2009, 23: 521-529. PMID: 19538046, PMCID: PMC3048777, DOI: 10.1089/apc.2008.0209.
• Low-Abundance HIV Drug-Resistant Viral Variants in Treatment-Experienced Persons Correlate with Historical Antiretroviral UseLe T, Chiarella J, Simen BB, Hanczaruk B, Egholm M, Landry ML, Dieckhaus K, Rosen MI, Kozal MJ. Low-Abundance HIV Drug-Resistant Viral Variants in Treatment-Experienced Persons Correlate with Historical Antiretroviral Use PLOS ONE 2009, 4: e6079. PMID: 19562031, PMCID: PMC2698118, DOI: 10.1371/journal.pone.0006079.
• Raltegravir With Unboosted Atazanavir 300 mg Twice Daily in Antiretroviral Treatment-Experienced ParticipantsGupta S, Lataillade M, Farber S, Kozal MJ. Raltegravir With Unboosted Atazanavir 300 mg Twice Daily in Antiretroviral Treatment-Experienced Participants Journal Of The International Association Of Providers Of AIDS Care (JIAPAC) 2009, 8: 87-92. PMID: 19270153, DOI: 10.1177/1545109709332471.
• Low-Abundance Drug-Resistant Viral Variants in Chronically HIV-Infected, Antiretroviral Treatment–Naive Patients Significantly Impact Treatment OutcomesSimen BB, Simons JF, Hullsiek KH, Novak RM, MacArthur RD, Baxter JD, Huang C, Lubeski C, Turenchalk GS, Braverman MS, Desany B, Rothberg JM, Egholm M, Kozal MJ. Low-Abundance Drug-Resistant Viral Variants in Chronically HIV-Infected, Antiretroviral Treatment–Naive Patients Significantly Impact Treatment Outcomes The Journal Of Infectious Diseases 2009, 199: 693-701. PMID: 19210162, DOI: 10.1086/596736.
• Drug-resistant human immunodefiency virusKozal MJ. Drug-resistant human immunodefiency virus Clinical Microbiology And Infection 2009, 15: 69-73. PMID: 19220361, DOI: 10.1111/j.1469-0691.2008.02687.x.
• Virologic, Immunologic, Clinical, Safety, and Resistance Outcomes from a Long-Term Comparison of Efavirenz-Based Versus Nevirapine-Based Antiretroviral Regimens as Initial Therapy in HIV-1—Infected Personsvan den Berg-Wolf M, Hullsiek KH, Peng G, Kozal MJ, Novak RM, Chen L, Crane LR, MacArthur RD, AIDS A. Virologic, Immunologic, Clinical, Safety, and Resistance Outcomes from a Long-Term Comparison of Efavirenz-Based Versus Nevirapine-Based Antiretroviral Regimens as Initial Therapy in HIV-1—Infected Persons HIV Research & Clinical Practice 2008, 9: 324-336. PMID: 18977721, DOI: 10.1310/hct0905-324.
• Review: Hepatitis C Protease and Polymerase Inhibitors in DevelopmentLiu-Young G, Kozal MJ. Review: Hepatitis C Protease and Polymerase Inhibitors in Development AIDS Patient Care And STDs 2008, 22: 449-457. PMID: 18479202, PMCID: PMC2928549, DOI: 10.1089/apc.2007.0199.
• Attitudes toward needle-sharing and HIV transmission risk behavior among HIV+ injection drug users in clinical careNorton WE, Amico KR, Fisher WA, Copenhaver MM, Kozal MJ, Cornman DH, Friedland G, Fisher JD. Attitudes toward needle-sharing and HIV transmission risk behavior among HIV+ injection drug users in clinical care AIDS Care 2008, 20: 462-469. PMID: 18449824, DOI: 10.1080/09540120701867081.
• Directly Administered Antiretroviral Therapy for HIV-Infected Drug Users Does Not Have an Impact on Antiretroviral ResistanceMaru DS, Kozal MJ, Bruce RD, Springer SA, Altice FL. Directly Administered Antiretroviral Therapy for HIV-Infected Drug Users Does Not Have an Impact on Antiretroviral Resistance JAIDS Journal Of Acquired Immune Deficiency Syndromes 2007, 46: 555-563. PMID: 18193497, PMCID: PMC2684061, DOI: 10.1097/qai.0b013e318158c0bd.
• The Incidence of HIV Drug Resistance and Its Impact on Progression of HIV Disease Among Antiretroviral-Naïve Participants Started on Three Different Antiretroviral Therapy StrategiesKozal MJ, Hullsiek KH, MacArthur RD, van den Berg-Wolf M, Peng G, Xiang Y, Baxter JD, Uy J, Telzak EE, Novak RM, AIDS F. The Incidence of HIV Drug Resistance and Its Impact on Progression of HIV Disease Among Antiretroviral-Naïve Participants Started on Three Different Antiretroviral Therapy Strategies HIV Research & Clinical Practice 2007, 8: 357-370. PMID: 18042501, DOI: 10.1310/hct0806-357.
• Evolution of Genotypic Resistance Algorithms and Their Impact on the Interpretation of Clinical Trials: An OPTIMA Trial SubstudyDesai S, Kyriakides T, Holodniy M, Al-Salman J, Griffith B, Kozal M. Evolution of Genotypic Resistance Algorithms and Their Impact on the Interpretation of Clinical Trials: An OPTIMA Trial Substudy HIV Research & Clinical Practice 2007, 8: 293-302. PMID: 17956830, DOI: 10.1310/hct0805-293.
• Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapiesBraithwaite RS, Kozal MJ, Chang CC, Roberts MS, Fultz SL, Goetz MB, Gibert C, Rodriguez-Barradas M, Mole L, Justice AC. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies AIDS 2007, 21: 1579-1589. PMID: 17630553, PMCID: PMC3460378, DOI: 10.1097/qad.0b013e3281532b31.
• Natural Polymorphism of the HIV-1 Integrase Gene and Mutations associated with Integrase Inhibitor ResistanceLataillade M, Chiarella J, Kozal MJ. Natural Polymorphism of the HIV-1 Integrase Gene and Mutations associated with Integrase Inhibitor Resistance Antiviral Therapy 2007, 12: 563-570. PMID: 17668566, DOI: 10.1177/135965350701200411.
• A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trialMacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Hullsiek KH, Kozal MJ, van den Berg-Wolf M, Henely C, Schmetter B, Dehlinger M, Team F, AIDS T. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial The Lancet 2006, 368: 2125-2135. PMID: 17174704, DOI: 10.1016/s0140-6736(06)69861-9.
• The Hunt for HIV-1 Integrase InhibitorsLataillade M, Kozal MJ. The Hunt for HIV-1 Integrase Inhibitors AIDS Patient Care And STDs 2006, 20: 489-501. PMID: 16839248, DOI: 10.1089/apc.2006.20.489.
• A population-based and longitudinal study of sexual behavior and multidrug-resistant HIV among patients in clinical care.Kozal MJ, Amico KR, Chiarella J, Cornman D, Fisher W, Fisher J, Friedland G. A population-based and longitudinal study of sexual behavior and multidrug-resistant HIV among patients in clinical care. Medscape Journal Of Medicine 2006, 8: 72. PMID: 16926811, PMCID: PMC1785162.
• A Population‐Based and Longitudinal Study of Sexual Behavior and Multidrug‐Resistant HIV Among Patients in Clinical CareKozal M, Amico K, Chiarella J, Cornman D, Fisher W, Fisher J, Friedland G. A Population‐Based and Longitudinal Study of Sexual Behavior and Multidrug‐Resistant HIV Among Patients in Clinical Care Journal Of The International AIDS Society 2006, 8: 72-72. PMCID: PMC2766001, DOI: 10.1186/1758-2652-8-2-72.
• HIV Drug Resistance and HIV Transmission Risk Behaviors Among Active Injection Drug UsersKozal MJ, Amico KR, Chiarella J, Cornman D, Fisher W, Fisher J, Friedland G. HIV Drug Resistance and HIV Transmission Risk Behaviors Among Active Injection Drug Users JAIDS Journal Of Acquired Immune Deficiency Syndromes 2005, 40: 106-109. PMID: 16123691, DOI: 10.1097/01.qai.0000159666.95455.d2.
• Prevalence and Impact of HIV-1 Protease Codon 33 Mutations and Polymorphisms in Treatment-Naive and Treatment-Experienced PatientsKozal MJ, Hullsiek KH, Leduc R, Novak RM, MacArthur RD, Lawrence J, Baxter JD. Prevalence and Impact of HIV-1 Protease Codon 33 Mutations and Polymorphisms in Treatment-Naive and Treatment-Experienced Patients Antiviral Therapy 2005, 11: 457-463. PMID: 16856619, DOI: 10.1177/135965350601100410.
• Prevalence of Antiretroviral Drug Resistance Mutations in Chronically HIV–Infected, Treatment-Naive Patients: Implications for Routine Resistance Screening before Initiation of Antiretroviral TherapyNovak RM, Chen L, MacArthur RD, Baxter JD, Hullsiek K, Peng G, Xiang Y, Henely C, Schmetter B, Uy J, van den Berg-Wolf M, Kozal M. Prevalence of Antiretroviral Drug Resistance Mutations in Chronically HIV–Infected, Treatment-Naive Patients: Implications for Routine Resistance Screening before Initiation of Antiretroviral Therapy Clinical Infectious Diseases 2005, 40: 468-474. PMID: 15668873, DOI: 10.1086/427212.
• Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical careKozal MJ, Amico KR, Chiarella J, Schreibman T, Cornman D, Fisher W, Fisher J, Friedland G. Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical care AIDS 2004, 18: 2185-2189. PMID: 15577652, DOI: 10.1097/00002030-200411050-00011.
• Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV-1 positive antiretroviral-naive persons.MacArthur RD, Chen L, Peng G, Novak RM, van den Berg-Wolf M, Kozal M, Besch L, Yurik T, Schmetter B, Henley C, Dehlinger M. Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV-1 positive antiretroviral-naive persons. HIV Clinical Trials 2004, 5: 361-70. PMID: 15682349, DOI: 10.1310/WEQG-QTHL-DL3X-FTXC.
• Review: Cross-Resistance Patterns Among HIV Protease InhibitorsKozal M. Review: Cross-Resistance Patterns Among HIV Protease Inhibitors AIDS Patient Care And STDs 2004, 18: 199-208. PMID: 15142350, DOI: 10.1089/108729104323038874.
• Using oligonucleotide probe arrays to access genetic diversityLipshutz R, Morris D, Chee M, Hubbell E, Kozal M, Shah N, Shen N, Yang R, Fodor S. Using oligonucleotide probe arrays to access genetic diversity 1999, 241-254. DOI: 10.1007/978-3-0348-8817-2_9.
• Extensive polymorphisms observed in HIV–1 clade B protease gene using high–density oligonucleotide arraysKozal M, Shah N, Shen N, Yang R, Fucini R, Merigan T, Richman D, Morris D, Hubbell E, Chee M, Gingeras T. Extensive polymorphisms observed in HIV–1 clade B protease gene using high–density oligonucleotide arrays Nature Medicine 1996, 2: 753-759. PMID: 8673920, DOI: 10.1038/nm0796-753.
• The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, Merigan TC. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Annals Of Internal Medicine 1996, 124: 1039-50. PMID: 8633817, DOI: 10.7326/0003-4819-124-12-199606150-00003.
• Using oligonucleotide probe arrays to access genetic diversity.Lipshutz RJ, Morris D, Chee M, Hubbell E, Kozal MJ, Shah N, Shen N, Yang R, Fodor SP. Using oligonucleotide probe arrays to access genetic diversity. BioTechniques 1995, 19: 442-7. PMID: 7495558.
• Detection of drug resistance mutations in the human immunodeficiency virus type 1 (HIV-1) pol gene: differences in semen and blood HIV-1 RNA and proviral DNA.Kroodsma KL, Kozal MJ, Hamed KA, Winters MA, Merigan TC. Detection of drug resistance mutations in the human immunodeficiency virus type 1 (HIV-1) pol gene: differences in semen and blood HIV-1 RNA and proviral DNA. The Journal Of Infectious Diseases 1994, 170: 1292-5. PMID: 7963730, DOI: 10.1093/infdis/170.5.1292.
• Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.Kozal MJ, Kroodsma K, Winters MA, Shafer RW, Efron B, Katzenstein DA, Merigan TC. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Annals Of Internal Medicine 1994, 121: 263-8. PMID: 7518658, DOI: 10.7326/0003-4819-121-4-199408150-00005.
• HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients.Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Aguiniga E, Halpern J, Merigan TC. HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1994, 7: 832-8. PMID: 7517448.
• Prevalence of HIV-1 syncytium-inducing phenotype.Kozal MJ, Ramachandran RV, Shafer RW. Prevalence of HIV-1 syncytium-inducing phenotype. Annals Of Internal Medicine 1994, 120: 811. PMID: 7908508, DOI: 10.7326/0003-4819-120-9-199405010-00019.
• Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.Shafer RW, Kozal MJ, Winters MA, Iversen A, Katzenstein DA, Ragni MV, Meyer WA, Gupta P, Rasheed S, Coombs R, Katzman M, Fiscus S, Merigan T. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. The Journal Of Infectious Diseases 1994, 169: 722-9. PMID: 8133086, DOI: 10.1093/infdis/169.4.722.
• Therapy of HIV-1 infectionKozal M, Merigan T. Therapy of HIV-1 infection Current Opinion In Infectious Diseases 1994, 7: 72-81. DOI: 10.1097/00001432-199402000-00013.
• HIV Resistance to Dideoxynucleoside InhibitorsKozal M, Merigan T. HIV Resistance to Dideoxynucleoside Inhibitors Infectious Diseases In Clinical Practice 1993, 2: 247-253. DOI: 10.1097/00019048-199307000-00002.
• Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy.Holodniy M, Katzenstein D, Winters M, Montoya J, Shafer R, Kozal M, Ragni M, Merigan TC. Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1993, 6: 366-9. PMID: 8095981.
• A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients.Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Merigan TC. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. The Journal Of Infectious Diseases 1993, 167: 526-32. PMID: 7680058, DOI: 10.1093/infdis/167.3.526.
• Zidovudine susceptibility testing of human immunodeficiency virus type 1 (HIV) clinical isolatesShafer R, Kozal M, Katzenstein D, Lipil W, Johnstone I, Merigan T. Zidovudine susceptibility testing of human immunodeficiency virus type 1 (HIV) clinical isolates Journal Of Virological Methods 1993, 41: 297-310. PMID: 8097199, DOI: 10.1016/0166-0934(93)90019-n.